Zoi Alexakou

Zoi Alexakou

Auto-generated profile, based on publicly available information

Zoi Alexakou

Department of Nephrology, Ippokrateion University Hospital, Athens, Greece

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 May 2023 in Kidney Research and Clinical Practice
Verified
Journal Article
Open access
PDF file
ADAikaterini Damianaki
Aikaterini Damianaki
ESEmelina Stambolliu
Emelina Stambolliu
ZAZoi Alexakou
Zoi Alexakou
DPDimitrios Petras
Dimitrios Petras
Hemoperfusion has been considered a promising adjuvant treatment for chronic diseases and some acute states when specific removal of pathogenic factors from the bloodstream is desired. Over the years, advances in adsorption materials (e.g., new synthetic polymers, biomimetic coating, and matrixes with novel structures) have renewed scientific interest and expanded the potential therapeutic indications of hemoperfusion. There is growing evidence to suggest a prominent place for hemoperfusion as an adjuvant treatment in the setting of sepsis or severe coronavirus disease 2019 and as a therapeutic option for chronic complications associated with accumulated uremic toxins in patients with end-stage renal disease. This literature review will describe the principles, therapeutic perspectives, and the emerging role of hemoperfusion as a complementary therapy for patients with kidney disease.